TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05644158

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Revascularization
Description: Depending on the exact morphology of the lesion, patients with short superficial femoral artery lesions (\<25 cm) will be subdivided into group 2A with endovascular treatment (percutaneous transluminal angioplasty with or without stenting) and patients with long superficial femoral artery lesions (\>25 cm) will be subdivided into group 2B with open surgical treatment (femoropopliteal bypass) .

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise therapy
Description: Home-based monitored exercise training (walking), 3 times a week, monitored with log book and activity sensors.
Study: NCT05380817

Intervention type: OTHER
Group type: OTHER
Intervention: Remote Monitoring Program
Description: Participants receive remote monitoring while engaging in a theory-based, multi-component, multi-level, multi-setting (MMM) community team sports program designed specifically for children

Intervention type: OTHER
Group type: OTHER
Intervention: Remote Monitoring Program
Description: Participants receive remote monitoring while engaging in a theory-based, multi-component, multi-level, multi-setting (MMM) community team sports program designed specifically for children
Study: NCT05005117

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic operation
Description: Operation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open operation
Description: Operation
Study: NCT05375760

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: AZD7442 (tixagevimab [AZD8895] + cilgavimab [AZD1061])
Description: Arm A - Day 1:~600 mg AZD7442 administered sequentially as a 3 mL IM injection containing 300 mg tixagevimab (AZD8895) and a 3 mL IM injection containing 300 mg cilgavimab (AZD1061), one injection in each gluteal region.~Arm A - Days 92, 183, 274, 365:~300 mg AZD7442 administered sequentially as a 1.5 mL IM injection containing 150 mg tixagevimab (AZD8895) and a 1.5 mL IM injection containing 150 mg cilgavimab (AZD1061), one injection in each gluteal region.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: AZD7442 (tixagevimab [AZD8895] + cilgavimab [AZD1061])
Description: Arm B - Day 1:~1200 mg AZD7442 (600 mg tixagevimab \[AZD8895\] and 600 mg cilgavimab \[AZD1061\]) administered by IV infusion.~Arm B - Days 183, 365:~600 mg AZD7442 administered sequentially as a 3 mL IM injection containing 300 mg tixagevimab (AZD8895) and a 3 mL IM injection containing 300 mg cilgavimab (AZD1061), one injection in each gluteal region.
Study: NCT05208099

Intervention type: BIOLOGICAL
Intervention: Blood tests
Description: For patients, it will be performed:~* a collection of blood samples (3 tubes of 5 mL) according to the usual medical management, in order to search for cardiovascular comorbidities associated with HS,~* A collection of 3 EDTA tubes and 2 additional dry tubes of 5 mL each according to the needs of the study.

Intervention type: PROCEDURE
Intervention: exeresis
Description: For patients, it will be performed:~- 6 tissue samples from the total excision specimen: two samples from the acute inflammatory zone (nodule, abscess, fistula) of 1 cm3; two samples from the chronic lesion zone (scar) of 1 cm3 and two samples from the peri-lesion zone (in the margin) of 1 cm3 on fresh tissue.

Intervention type: PROCEDURE
Intervention: abdominoplasty
Description: For the controls, 6 fresh skin samples of 1 cm3 each will be taken from the abdominoplasty operation:~* four in the center,~* two in the margin
Study: NCT06074341

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based relapse prevention
Description: Mindfulness-based relapse prevention (MBRP) is a group-based treatment to provide individuals with skills intended to foster increased awareness of triggers, destructive habitual patterns, and automatic reactions to triggering experiences. Mindfulness practices in MBRP are designed to help individuals pause, observe present experience, and bring awareness to the range of choices available in every moment. Through MBRP individuals learn to respond in ways that serve them, rather than react in ways that are detrimental to their health and happiness.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Online Mutual Support Groups
Description: Mutual support groups are free, peer-led organizations that are designed to help individuals with substance use disorders and other addiction-related problems. Mutual support groups often focus on communication and exchange of addiction and recovery experience and skills. Individuals participate in activities that engage, educate, and support patients recovering from substance use disorder from others facing similar challenges. Mutual help organizations that will be offered as referrals include: Alcoholics Anonymous (AA), In The Rooms, and SMART Recovery.
Study: NCT05156034

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SRK-001
Description: Participants will receive IV doses of SRK-001.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SRK-001
Description: Participants will receive IV doses of SRK-001.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SRK-001
Description: Participants will receive IV doses of SRK-001.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive IV doses of placebo.
Study: NCT05067725

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CarePath
Description: During an in-clinic patient encounter with a primary care provider (PCP) in any one of the intervention CMSL sites, the BPA is fired when any type of headache or migraine is entered as a diagnosis or chief complaint. The purpose of the headache assessment questionnaire is to assist the PCP in characterizing patients' headache. The Express Lane will help guide PCP decision-making for prescribing medications, lab/image ordering, and referrals. The Ask-a-doc button will provide timely access to a virtual treatment and diagnosis consult with a neurologist.
Study: NCT05064215

Intervention type: PROCEDURE
Intervention: anatomical examination
Description: After injection of dye, its distribution along lymphatic clearance paths was investigated

Intervention type: PROCEDURE
Intervention: anatomical examination
Description: After injection of dye, its distribution along lymphatic clearance paths was investigated

Intervention type: PROCEDURE
Intervention: anatomical examination
Description: After injection of dye, its distribution along lymphatic clearance paths was investigated
Study: NCT06177548

Intervention type: PROCEDURE
Intervention: Minimally invasive Bentall procedure
Description: The minimally invasive Bentall procedure is performed through a small incision in the right intercostal space.
Study: NCT04843462

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: edupression.com®
Description: Edupression.com® is an evidence-based self-help program that was developed for the treatment of mild to moderate unipolar depression. It is based on two core foundations, psychoeducation with elements of cognitive behavior therapy (CBT) and a mood chart. Both foundations are registered as a medical product. As such, detailed risk management documentation includes probability and severity of adverse events. Moreover, detailed strategies such as warnings were implemented in the software and documented accordingly.~It can be used on a PC as well as on mobile devices (browser, app) at any time.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine nasal spray
Description: All patients included in this study are receiving esketamine nasal spray as treatment-as-usual

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esketamine nasal spray
Description: All patients included in this study are receiving esketamine nasal spray as treatment-as-usual
Study: NCT05342714

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Remote ischemic conditioning
Description: The LRIC treatment consisted of 5 cycles of bilateral upper limb ischemia for 5 minutes followed by reperfusion for another 5 minutes performed twice a day for a total of 180 consecutive days.The procedure was performed by using an electric autocontrol device with cuffs that inflated to a pressure of 200 mmHg during the ischemic period and deflated during the reperfusion.(Patent No.CN200820123637.X, China).
Study: NCT04731558

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enoxaparin or tinzaparin or dalteparin
Description: Thromboprophylaxis initiated approximately 14 hours prior to the planned liver resection skin incision. Thromboprophylaxis can be initiated using enoxaparin (20 - 40 mg), tinzaparin (2500 - 4500 IU), or dalteparin (2500 - 5000 IU), with the dose based on patient's renal function

Intervention type: DRUG
Group type: OTHER
Intervention: No intervention
Description: No preoperative thromboprophylaxis.
Study: NCT06521333

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Resveratrol-Based gel
Description: The Resveratrol-Based gel will be applied using a sterile plastic syringe, and the palatal wound will be immediately covered by an acrylic resin stent. Three days postoperatively, the patients will be recalled, the stent will be removed for evaluation and the Resveratrol gel will be reapplied.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronic acid gel 0.2%
Description: The 0.2% Hyaluronic acid gel will be applied using a sterile plastic syringe, and the palatal wound will be covered by an acrylic resin stent. Three days postoperatively, the patients will be recalled, the stent will be removed for evaluation, and the Hyaluronic acid gel will be reapplied.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Stent
Description: The palatal wound will be immediately covered by acrylic resin stent three days postoperatively, the patients will be recalled, and the stent will be removed for evaluating the healing of the palatal wound and then recover with stent.
Study: NCT05556837

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control Cereal
Description: A portion of cereal (25g available carbohydrate), served with 125ml of 2% milk and 250ml water, will be fed to participants and postprandial glucose and insulin will be measured

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OBG Cereal
Description: A portion of cereal (25g available carbohydrate) containing OBG, served with 125ml of 2% milk and 250ml of water, will be fed to participants and postprandial glucose and insulin will be measured

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BBG Cereal
Description: A portion of cereal (25g available carbohydrate) containing BBG, served with 125ml of 2% milk and 250ml of water, will be fed to participants and postprandial glucose and insulin will be measured
Study: NCT05173753

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Novel self-adhesive hybrid composite(Surefil one)
Description: Surefil one, is a recent introduced esthetic dental restoration for treatment of carious teeth.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Novel self-adhesive hybrid composite(Surefil one)
Description: Surefil one, is a recent introduced esthetic dental restoration for treatment of carious teeth.
Study: NCT06272396

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smart watch
Description: ECG 1D/6D
Study: NCT06462599

Intervention type: GENETIC
Intervention: Gene polymorphism from blood samples
Description: Blood samples will be collected from stroke patients within 24 hrs of stroke and normal volunteers.~Two samples will be collected serum and plasma; five ml whole blood from patients and normal volunteers and centrifuge serum samples at 1500 rpm 10 min then will be stored at - 80 °C until the day of the analysis.~Plasma samples will be stored at - 80 °C until the day of the analysis without centrifugation

Intervention type: GENETIC
Intervention: Gene polymorphism from blood samples
Description: Blood samples will be collected from stroke patients within 24 hrs of stroke and normal volunteers.~Two samples will be collected serum and plasma; five ml whole blood from patients and normal volunteers and centrifuge serum samples at 1500 rpm 10 min then will be stored at - 80 °C until the day of the analysis.~Plasma samples will be stored at - 80 °C until the day of the analysis without centrifugation
Study: NCT06492525

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ensartinib
Description: 225 mg oral dose on day 1 in period 1 and on day 18 in period 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin
Description: 600 mg QD from day 9 to day 22 in period 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: 200 mg QD from day 9 to day 19 in period 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ensartinib
Description: 100 mg oral dose on day 1 in period 1 and on day 12 in period 2
Study: NCT04968275

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CHAMPS
Description: CHAMPS provides personalized feedback on participants' cannabis use behaviors and supports strategies to change such behaviors. It comprises six modules measuring the use of cannabis protective behavioural strategies, exploring the possible benefits of changing cannabis practices and setting and monitoring the reach of a SMART cannabis use goal.
Study: NCT05438303

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9833
Description: AZD9833 tablets will be administered orally once daily on Days 1 - Day 5 (Treatment Period 2) and Day 1 (Treatment Period 3) for participants recruited to Arms A and C and Day 1 for those in Arm B

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9833
Description: AZD9833 tablets will be administered orally once daily on Days 1 - Day 5 (Treatment Period 2) and Day 1 (Treatment Period 3) for participants recruited to Arms A and C and Day 1 for those in Arm B

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9833
Description: AZD9833 tablets will be administered orally once daily on Days 1 - Day 5 (Treatment Period 2) and Day 1 (Treatment Period 3) for participants recruited to Arms A and C and Day 1 for those in Arm B

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Midazolam will be administered orally as a syrup once on Day 1 of Treatment Periods 1 and 3; administered together with Omeprazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: An Omeprazole capsule will be administered once on Day 1 of Treatment Periods 1 and 3; administered together with Midazolam

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabigatran Etexilate
Description: A Dabigatran Etexilate capsule will be administered once on Day 1 of Treatment Periods 1 and 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: A Celecoxib capsule will be administered once on Day 1 of Treatment Periods 1 and 3
Study: NCT04844398

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clown visits by RED NOSES Clowndoctors Austria
Description: Participants will receive one clown visit per week over four weeks in a group setting. The visits will take place in at least two different wards of each participating psychiatric care facility. In each ward, max. 10 participants will be targeted. The visits are carried out routinely by two professional clown artists from RED NOSES Clowndoctors Austria. The duration of the visits and the specific artistic sequences will take place according to internally organized routines. The essence of the clown visit is to catch the patient's attention proactively and reach the highest level of engagement possible. The specific artistic sequences are implemented spontaneously according to the situational atmosphere and current mood of participants. One clown visit will last between 1 and 2 hours depending on age and number of participants. Each participant will be engaged between 5 and 10 minutes by the clown. The clown artists are not involved in any study-related research activities.
Study: NCT05271877

Intervention type: PROCEDURE
Intervention: Laparoscopy
Description: Diagnostic/operative laparoscopic procedure
Study: NCT03705338

Intervention type: DEVICE
Intervention: Electroencephalography
Description: Measure the appearance and disappearance of frontal alpha wave with EE, when them loss and recovery of consciousness under general anesthesia with propofol.

Intervention type: DRUG
Intervention: Propofol
Description: Recorder the loss and recovery of consciousness in children under general anesthesia with TCI of propofol intravenous. Induction will be started with 20 mg/kg/hr of propofol up to UMSS level 4. Then will be titrated leading anesthesiologist criteria.
Study: NCT05593978

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Culinary Medicine
Description: The CM-group will receive weekly cooking demonstrations and education videos via electronic links for 16 weeks, and three nutrition education based on the content of the Nutrition Care Manual from the Academy of Nutrition and Dietetics to show age-appropriate recipes with correct preparation methods and different cooking methods for lean ground red meat to increase protein consumption.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Control
Description: The CN-group will receive weekly recipes via electronic links without the culinary medicine intervention.
Study: NCT06069375

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium phenylbutyrate
Description: Open-label design with doses of sodium phenylbutyrate up to 4.0 g/m2/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium phenylbutyrate
Description: Open-label design with doses of sodium phenylbutyrate up to 4.0 g/m2/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium phenylbutyrate
Description: Open-label design with doses of sodium phenylbutyrate up to 4.0 g/m2/day
Study: NCT04904614

Intervention type: DRUG
Group type: OTHER
Intervention: Letermovir
Description: Open label trial of the licensed drug, letermovir, in a population of heart transplant recipients for which it is not yet licensed
Study: NCT05624970

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: aerobic training , tobacco cessation and nutritional advices
Description: 1. Aerobic training program according to Taheri et al 2017:~   * Mode: recruits large groups of muscles and includes brisk walking on treadmill, cycling, swimming, and jogging~  * Intensity: submaximal aerobic exercise program (50-60% of maximal heart rate reserve) on treadmill~  * Frequency: 3 sessions a week for 2 months.~  * Duration: 60 min/session The training protocol was divided into three phases: the warm up period (10 minutes), the main program (aerobic exercise; 40 minutes), and a cool down period (10 minutes).~2. Tobacco Cessation Programs for 3 months~3. Nutritional advices according to American Diabetes Association (ADA) 2015: for 3 months

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: tobacco cessation and nutritional advices
Description: Tobacco Cessation Programs for 3 months Nutritional advices according to American Diabetes Association (ADA) 2015: for 3 months
Study: NCT05796934

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moments that Matter (MTM) Program
Description: MTM aims to empower caregivers, enhance nurturing care practices, and ultimately improve early child development (ECD). MTM will be targeted to primary caregivers of children aged 0-3 years and implemented over an 18 month period. The primary program delivery agent will be local volunteers (ECD promoters) who will facilitate monthly peer group sessions and conduct monthly home visits to participants residing in their village. The MTM curriculum covers topics relating to responsive caregiving, early learning, and child security \& safety, and gender equality. Faith leaders will also be trained to promote nurturing care and ECD within their sermons and Bible study groups. ECD committees will be also formed among leaders across various sectors (e.g., health, education, faith institutions) to promote nurturing care and ECD at the community level and coordinate MTM activities with program staff, delivery agents, and other existing service providers (e.g., community health volunteers).
Study: NCT05744674

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HR18034
Description: HR18034 228mg/342mg/456mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine Hydrochloride Injection
Description: Ropivacaine Hydrochloride Injection 60mg/90mg/120mg
Study: NCT05198596

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVC-COV1901
Description: Approximately125 participants will receive 2 doses of MVC-COV1901(S-2P protein with adjuvant) at Day 1 and Day 29 via intramuscular (IM) injection in the deltoid region

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: AZD1222
Description: Approximately 125 participants will receive 2 doses of AZD1222 at Day 1 and Day 29 via intramuscular (IM) injection in the deltoid region
Study: NCT05043662

Intervention type: DIAGNOSTIC_TEST
Intervention: UroCAD assay, CTU examination and urine cytology
Description: The extracted DNA from morning urine will be analyzed by UroCAD to determine the level of CNV. CTU and cytology will be performed according to the routine of clinical practice.

Intervention type: DIAGNOSTIC_TEST
Intervention: UroCAD assay, CTU examination and urine cytology
Description: The extracted DNA from morning urine will be analyzed by UroCAD to determine the level of CNV. CTU and cytology will be performed according to the routine of clinical practice.
Study: NCT05235269

Intervention type: DRUG
Group type: OTHER
Intervention: I124-AT01 only
Description: Intravenous injection of I124-AT01 on Day 1 and again at Week 6 followed by a full body Positron Emission Tomography/Computed Tomography (PET/CT) scan.
Study: NCT06171243

Intervention type: DRUG
Intervention: Lidocaine topical
Description: Patients who agree to participate, will be given the Lidocaine 23%/Tetracaine 7% formulation. The application of the cream will be carried out by a researcher in charge:~1. A skin area of 200 cm2 will be delimited for the application of the formulation throughout the study period.~2. 10 grams will be applied every 12 hours for a period of 48 hours.
Study: NCT05571332

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avatrombopag 20 MG Oral Tablet
Description: p-ATG and CsA in combination with Avatrombopag to treat
Study: NCT05788159

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacosamide Tablets
Description: Reference preparation (R): Lacosamide Tablets Specification: 50mg/tablet Lot No.: 7883201 Content: 50mg/tablet Expiration date: September 2026 Storage condition: not more than 30C in airtight storage Manufacturer: Aesica Pharmaceuticals GmbH

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lacosamide extended release tablets
Description: Test preparation (T): Lacosamide extended release tablets Specification: 100mg/tablet Lot number: 22121301 Content: 100mg/tablet Expiration date: December 12, 2024 Storage conditions: Store at 20℃\~25℃, short-term can be at 15C\~30℃ Manufacturer: Overseas Pharmaceutical,Ltd.